What Investors Still Cannot See And Where the Alpha Is Hiding
This week’s dispatch includes the book I wish I’d had at the start plus five new signals shaping the future of women’s health investing.
This newsletter is 100% free. But it takes hours each week to research, write, and produce at this level. Here are 5 ways to support my work: 1. click “❤️” to amplify 2. subscribe 3. share this publication 4. buy me coffee 5. become a partner
📲 connect and collaborate with me here! email | LinkedIn | Instagram
Dear Reader,
This week, in conversation with a healthcare investor, I was reminded just how invisible some of the most urgent innovations still are to capital markets. Not because the science isn’t strong. Not because the demand isn’t real. But because we still don’t have the frameworks to see them clearly.
It struck me again how capital gaps don’t always begin with rejection. Sometimes, they begin with absence. With a pitch no one knows how to price. A signal no one’s been trained to read.
This week’s dispatch is about those blind spots and the work of making them visible:
a preview of The Billion Dollar Blind Spot - the book I wish I’d had at the start
an investor brief on how FDA-cleared AI, Amazon’s fertility move, and hormone tracking are turning women’s health into real infrastructure.
And a new global partnership with Femtech Weekend, where we are helping grow the next generation of women’s health insight and visibility
Let’s get into it.
The Book I Wish I’d Had
What if the most promising companies don’t fail because they are weak but because we have never been taught how to see their strength? This piece is about the blind spots that nearly stalled Gynesonics, and the book I wrote to make sure it doesn’t happen again.
📣 New: The Billion Dollar Blind Spot
I’m writing the strategic investing guide I wish I’d had at the start.
It’s for anyone; men, women, allocators, skeptics who wants to learn how to spot real alpha in women’s health.
👉 Join the waitlist here for early access
When Amazon Bets on Fertility and the FDA Clears Predictive AI
Progyny joins Amazon’s health benefits platform. Clarity secures FDA clearance for predictive AI. But what if these aren’t isolated wins but clues to a deeper shift? This week’s Signal Not Noise brief unpacks how regulated tech and enterprise channels are quietly redrawing the capital map in women’s health.
Building the Global Conversation Around Women’s Health Innovation
Strategic capital doesn’t just follow data. It follows visibility, insight, and trust. That’s why we partnered with Femtech Weekend: to help grow the global conversation. This brief unpacks how aligning with founder-led communities is part of our long game to shape the future ecosystem for women’s health.
👋 Ready to Learn How to Invest?
This September, we are opening a new cohort of the Investor Readiness Program; a 6-week, immersive course for women who want to confidently invest in health innovation.
No jargon. No hedge fund background required. Just the desire to understand how capital shapes change.
❤️ Enjoying this? If this post sparked something for you, click the ❤️ at the bottom. It helps more than you know and tells me you're reading.
Coming in July 2025:
🎧 Blindspot Capital: The Podcast
Formerly FemmeHealth Founders, our podcast relaunches this summer under a sharper lens and a bolder name. Blindspot Capital explores the undercurrents shaping health innovation from the deals that stall to the systems that silence. Confirmed guests include:
💥 Ida Tin (Clue, FemTech Assembly) on founding the femtech category
🧠 Lisa Suennen (venture partner & healthtech strategist) on how institutional capital moves.👉 Subscribe to Blindspot Capital wherever you get your podcasts, or listen directly on Substack.
We write weekly at FemmeHealth Ventures Alliance about capital, care, and the future of overlooked markets. If you are building, backing, or allocating in this space, I’d love to connect.
👉 ICYMI - Our Latest Publications
The Book I Wish I’d Had: A Strategic Guide to Investing in Women’s Health Innovation
Menstrual Fatigue Relief: How Pharmalp’s Femina Cycles Is Quietly Innovating Women's Health
How to Start Angel Investing in Women’s Health with Just $1K
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
